




# **Veeda Group: Integrated, Tech-Driven, Global CRO**

# Our Support Spans the Entire Spectrum of Drug Development Phases



## Preclinical Capabilities: A Foundation for Success

### Generics Preclinical

- Impurity qualification (Ames test, Enhanced Ames, In vitro CAT, systemic tox)
- ANDA/NDA, 505(B)2 toxicity studies
- Analytical & Bioanalytical MD, MV & analysis
- Nonclinical Biodistribution studies (Complex injectables - FCM, Iron sucrose & liposomal drugs)
- Environmental risk assessment (ERA): Tier based, Phys-chem, Ecotoxicology

**300+ impurity qualification studies**

### Innovators (NCE/Small molecules)

- DMPK/ Standalone PK
- IND enabling studies
- Inhalation Toxicity
- Genetic toxicity
- DART/Reprotox

**Team of 450+ scientists**

### Biopharma Preclinical

- Safety / Toxicity with Immunogenicity assessment
- Custom HCP assay dev., mAbs, pAbs generation
- Biological assays

**23,500+ GLP studies**

### Synthetic, Chemistry Services

- Medicinal chemistry, Custom Synthesis, Process R&D and scale up
- Synthesis of novel scaffolds, building blocks & NCEs
- Isolation, Characterization, Identification & Synthesis of Impurities

**One of the Largest Vivarium in the Country with 115 animal rooms**



# Comprehensive Bioequivalence Expertise: Supporting Healthy Volunteer Studies

- Expertise in Healthy Volunteer Bioequivalence (BE) Studies; Specialization in Complex Generics & Biosimilars
- 4,900+ Successfully Completed Healthy Volunteer Studies
- 85,000+ Volunteer Database

## Early Phase Trial Capabilities: Extensive Assistance for a Diverse Range of Complex Drug Products


- Phase I First-in-Human, Single Ascending Dose (SAD) /Multiple Ascending Dose (MAD) & Proof of Concept Studies for New Chemical Entities (NCEs)
  - 588 Beds & 22 Special Beds Across 16 Clinics
  - 30 Intensively Monitored Beds for Phase I / First-in-Human Studies

Partnered with 19 Unique Sponsors for Phase I Studies Globally

## Enhancing the Potential of Your Complex Generic Portfolio with our Comprehensive Capabilities

Experience in Handling **230+** Complex Generic Studies

**Leaders in Injectable Research: Including 18 Long-Acting Formulations**



- Glucose Clamp Studies
- Patches Studies
- Studies via 505(b)(2) Pathway
- Phase I Studies
- Injectable Studies
- Suppositories Studies
- Inhalation Studies



# Precision and Compliance in Clinical Trials: From Design to Delivery

## Clinical Studies Execution across 26 Geographies; US, EU, and Asia-Pacific Regions

- Expertise in Patient Bioequivalence (BE) Studies; Clinical End Point & Pharmacokinetic (PK) Studies
- Innovator Drug Development Trials; Phase I to Phase III Trials for New Chemical Entities (NCEs) & Novel Biologic Entities (NBEs)
- Phase III Biosimilar Trials; Advancing Biosimilar through Phase III trials, evaluating Safety, Efficacy, and Immunogenicity
- Phase I/III Integrated Studies for Oncology Biosimilars
- Phase IV Studies; PMS Studies & Pharmacovigilance services

**Leading CRO** supporting the fight against Multiple Myeloma

**10,000+**

Patient Database

**750+**

Sites

**1800+**

Investigator Database

**20+**

Ongoing Phase I-IV Trials

**55+ Patient**


Bioequivalence  
Studies

**40+ Oncology trials**

**Regulatory Excellence: 27 USFDA & 2 EMA Inspections  
with Zero 483 Observations**



# Leveraging e-Clinical Platforms to Accelerate Trials



## Advanced Bioanalytical Expertise: Method Development, Validation and Sample Analysis

Over **1240+** bioanalytical methods with an average runtime of under 5 minutes, covering diverse categories.

**1008 + 21**

Generics + Pharmacodynamics/  
Immunogenicity

**112**

Complex Generics

**101**

NCEs

### Laboratory Infrastructure

- LC-MS/MS, ICP-OES, ICP-MS, LHS & LIMS machines
- BSL class-2 lab for Infectious Samples
- Deep Freezers and Cold Room for Plasma Samples
- Pharma Refrigerators, Walk-In & Humidity Chambers




### Timeliness & Technical Expertise

- Uniquely Positioned to rapidly advance NCE development using SFC-MS/MS
- Capable of Processing 1,20,000 samples per month
- Complex molecule method development <3weeks
- Sample analysis, within 5 days to support FIH study for NCE dose escalation studies.
- >240 Trained and competent scientific team to handle regulated bioanalysis.
- ISR acceptance > 97%




# Veeda Biopharma: Customized Integrated Solutions across Different Modalities

We specialize in catering to the diverse R&D requirements of global biopharmaceutical & biotechnology clients across a wide array of modalities.



## One-Stop Solution for Novel Therapeutics and Biosimilars



**145 Successful Regulatory Audits to Date**



+91 79677 73000



info@veedalifesciences.com



www.veedalifesciences.com

**Excellence**  
**In Everything**